 SAN DIEGO, June 25, 2021 PRNewswire -- Regulus Therapeutics Inc. Nasdaq: RGLS, a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs the Company or Regulus, today announced the presentation of additional data from the first cohort of patients in the Companys Phase 1b clinical trial of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease ADPKD, as well as new preclinical data from relevant animal models of the disease. The E-poster presentation, titled Preclinical Evaluation and Results from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ADPKD, is available to attendees of the PKD Connect Conference 2021, on Friday, June 25, from 2-3 p.m. 